http://www.asco.org/quality-guidelines/systemic-therapy-men-metastatic-castration-resistant-prostate-cancer-crpc "Methods: The American Society of Clinical Oncology and Cancer Care Ontario convened an Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature.
Results (among others): For asymptomatic/minimally symptomatic men, improved survival with unclear QOL impact and low toxicity are associated with sipuleucel-T.
Recommendations (among others): Sipuleucel-T may be offered to asymptomatic/minimally symptomatic men.
There is insufficient evidence evaluating optimal sequences or combinations of therapies."
Is this why DNDN has been climbing? Can we expect a relatively stellar 4th quarter?
LookoutJoe